• I received my M.D. degree from the University of Modena in Italy, and received internal medicine and medical oncology training at the university of Milan, in Italy, where I focused on the management of hematologic malignancies and hematopoietic stem cell transplantation. Following my fellowship, I joined the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston, TX) for post-doctoral studies, where I completed the pre-clinical validation of an immunotherapy protocol for the treatment of relapsed Hodgkin lymphoma, and the clinical validation of a novel suicide gene safety switch for graft-versus-host-disease occurring after donor lymphocyte infusion. Afterwards, I underwent ECFMG certification and moved to the University of Texas MD Anderson Cancer Center for Bone Marrow Transplantation fellowship and clinical research, especially regarding myelodysplastic syndromes, acute myeloid leukemia, and haploidentical hematopoietic stem cell transplantation. My interest is to provide clinical care to patients with hematological malignancies, myelodysplastic syndromes, acute leukemias and lymphomas while being directly involved in laboratory research as well. My passion is to dedicate myself to the discovery of novel immunotherapy strategies for disease eradication and conditioning to a hematopoietic stem cell transplantation, as well as strategies to control the toxicities of those novel forms of treatment.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Hematopoietic cell transplantation, Version 2.2020 2020
    2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow ResultsClinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
    2019 Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AMLNew England Journal of Medicine.  381:1728-1740. 2019
    2019 Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDSBone Marrow Transplantation.  54:1245-1253. 2019
    2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsBiology of Blood and Marrow Transplantation.  25:233-238. 2019
    2019 Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for cancer immunotherapyMethods in Molecular Biology.  1895:57-73. 2019
    2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
    2017 Exploiting cell death pathways for inducible cell elimination to modulate graft-versus-host-diseaseBiomedicines.  5. 2017
    2017 Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.PLoS ONE.  12:e0172640. 2017
    2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failureBone Marrow Transplantation.  52:157-158. 2017
    2016 In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemiaPLoS ONE.  11. 2016
    2016 Novel toxicology challenges in the era of chimeric antigen receptor T-cells therapiesTranslational cancer research.  5:S444-S449. 2016
    2015 Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationBlood.  125:4103-4113. 2015
    2015 Seatbelts in CAR therapy: How safe are CARS?Pharmaceuticals.  8:230-249. 2015
    2015 Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?Biology of Blood and Marrow Transplantation.  21:713-719. 2015
    2015 Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaquesSTEM CELLS.  33:91-100. 2015
    2015 Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studiesFrontiers in Immunology.  6. 2015
    2015 iCaspase 9 suicide gene systemMethods in Molecular Biology.  1317:87-105. 2015
    2014 Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgeneBlood.  123:3895-3905. 2014
    2014 Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stemcell transplantationBiology of Blood and Marrow Transplantation.  20:1767-1771. 2014
    2014 Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experienceInternational Journal of Hematology.  100:457-463. 2014
    2014 Improving the safety of cell therapy products by suicide gene transfer.Frontiers in Pharmacology.  5:254. 2014
    2014 Lenalidomide-induced graft-Vs.-leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplantClinical Lymphoma, Myeloma and Leukemia.  14. 2014
    2014 Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donorsBiology of Blood and Marrow Transplantation.  20:1975-1981. 2014
    2014 The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantationClinical Lymphoma, Myeloma and Leukemia.  14. 2014
    2013 Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.American Journal of Blood Research.  3:260-264. 2013
    2011 Inducible apoptosis as a safety switch for adoptive cell therapyNew England Journal of Medicine.  365:1673-1683. 2011
    2010 Gene therapy to improve migration of T cells to the tumor site.Methods in Molecular Biology.  651:103-118. 2010
    2010 Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: A single institution experience 2010
    2009 T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor modelBlood.  113:6392-6402. 2009
    2007 Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBlood.  110:2620-2630. 2007
    2002 FOLFOX 2 regimen in heavily pretreated patients with advanced colorectal cancer 2002


    Year Title Altmetric
    2016 The old and the new-integrating prognostic models and mutational advances with epigenetic and cellular therapies for myelodysplastic syndromes.  219-242. 2016
    2014 Hematopoietic Cell Transplantation in Myelodysplastic Syndromes.  126-130. 2014

    Research Overview

  • T-cell Immunotherapy for leukemias and lymphomas
    Hematopoietic stem cell transplantation
    Suicide gene strategies for the safety of cellular therapies
  • Investigator On

  • BMT CTN 1703/1801 A Randomized, Multicenter Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation and Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)  awarded by National Marrow Donor Program 2019 - 2025
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by MUNDIPHARMA 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • IUAB 1677: Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib  awarded by VANDERBILT UNIVERSITY 2017 - 2022
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW 2018 - 2021
  • A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRaß+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801  awarded by Childrens Hospital Los Angeles 2019 - 2020
  • Private Grant  awarded by ONYX PHARMACEUTICALS, INC. 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Generation of Suicide Gene Modified Anti-CD19 CAR Redirected T Cells  awarded by St. Baldrick's Foundation 2017 - 2019
  • BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma  awarded by National Marrow Donor Program 2017 - 2019
  • Private Grant  awarded by FATE THERAPEUTICS, INC. 2016 - 2018
  • Education And Training

  • Doctor of Medicine, University of Modena and Reggio Emilia 2001
  • Istituto Nazionale dei Tumori, Residency 2004
  • MD Anderson Cancer Center, Postdoctoral Fellowship 2013
  • Baylor College of Medicine, Postdoctoral Fellowship 2009
  • Full Name

  • Antonio Di Stasi